122 related articles for article (PubMed ID: 30605998)
1. Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with VEGF and PDGFR.
Watanabe S; Suzuki T; Kondo Y; Naoe A; Uga N; Yasui T; Hara F; Tsuchiya T
Minerva Pediatr (Torino); 2023 Aug; 75(4):561-566. PubMed ID: 30605998
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma.
Gheytanchi E; Mehrazma M; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(7):3065-70. PubMed ID: 24815448
[TBL] [Abstract][Full Text] [Related]
3. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
4. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
5. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
[TBL] [Abstract][Full Text] [Related]
6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of cell proliferation in human neuroblastoma: comparison with other prognostic factors.
Mejía C; Navarro S; Pellín A; Ruíz A; Castel V; Llombart-Bosch A
Oncol Rep; 2003; 10(1):243-7. PubMed ID: 12469176
[TBL] [Abstract][Full Text] [Related]
8. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
9. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
10. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
[TBL] [Abstract][Full Text] [Related]
11. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
12. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.
Kang J; Rychahou PG; Ishola TA; Mourot JM; Evers BM; Chung DH
Oncogene; 2008 Jun; 27(28):3999-4007. PubMed ID: 18278068
[TBL] [Abstract][Full Text] [Related]
13. The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.
Yi B; Yang J; Wang L
Tumour Biol; 2014 Apr; 35(4):3229-35. PubMed ID: 24293393
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling pathway in neuroblastoma differentiation.
Souzaki R; Tajiri T; Souzaki M; Kinoshita Y; Tanaka S; Kohashi K; Oda Y; Katano M; Taguchi T
J Pediatr Surg; 2010 Dec; 45(12):2299-304. PubMed ID: 21129534
[TBL] [Abstract][Full Text] [Related]
15. Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.
Pezzolo A; Parodi F; Marimpietri D; Raffaghello L; Cocco C; Pistorio A; Mosconi M; Gambini C; Cilli M; Deaglio S; Malavasi F; Pistoia V
Cell Res; 2011 Oct; 21(10):1470-86. PubMed ID: 21403679
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
17. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
19. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
20. The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.
Amoroso F; Capece M; Rotondo A; Cangelosi D; Ferracin M; Franceschini A; Raffaghello L; Pistoia V; Varesio L; Adinolfi E
Oncogene; 2015 Oct; 34(41):5240-51. PubMed ID: 25619831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]